‘Caged … For No Fault of Your Own’: Detainees Dread Covid While Awaiting Immigration Hearings
Covid remains a threat for the roughly 30,000 people in the country’s network of immigration facilities. But ICE continues to flout its own pandemic protocols, an extension of the facilities’ poor history of medical care.
Inmigrantes detenidos en centros enfrentan riesgo de covid como al inicio de la pandemia
Para las aproximadamente 30,000 personas que viven en espacios cerrados en la red de instalaciones de detención de inmigrantes del país, covid sigue siendo una amenaza constante.
Readers and Tweeters Chime In on Disability Rights and Drug Discounts
KHN gives readers a chance to comment on a recent batch of stories.
KHN’s ‘What the Health?’: Health Spending? Only Congress Knows
Top negotiators in Congress have agreed to a framework for government spending into next year, but there are details to iron out before a vote — such as the scheduled Medicare payment cuts that have providers worried. Also, the Biden administration reopens its program allowing Americans to request free covid-19 home tests, as hopes for pandemic preparedness measures from Congress dim. Rachel Cohrs of Stat, Alice Miranda Ollstein of Politico, and Rebecca Adams of KHN join KHN’s Mary Agnes Carey to discuss these topics and more. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week they think you should read, too.
Paxlovid Has Been Free So Far. Next Year, Sticker Shock Awaits.
The government soon will stop paying for the covid drug that has proved to be the most effective at keeping patients alive and out of the hospital.
The Business of Clinical Trials Is Booming. Private Equity Has Taken Notice.
Private equity-backed Headlands Research heralded its covid-19 vaccine trials as a chance to boost participation among diverse populations, then it shuttered multiple sites that conducted them.
Para lanzar un nuevo fármaco al mercado, la Administración de Alimentos y Medicamentos (FDA) exige a las farmacéuticas estudios exhaustivos para demostrar su seguridad y eficacia. Conseguir que un medicamento salga al mercado unos meses antes, y con menos gastos de lo habitual, puede traducirse en beneficios millonarios para el fabricante.
KHN’s ‘What the Health?’: Medicaid Machinations
The lame-duck Congress has returned to Washington with a long health care to-do list and only a little time. Meanwhile, some of the states that have not yet expanded Medicaid eligibility under the Affordable Care Act are rethinking those decisions. Alice Miranda Ollstein of Politico, Rachel Cohrs of Stat, and Sarah Karlin-Smith of the Pink Sheet join KHN’s Julie Rovner to discuss these topics and more. Also this week, Rovner interviews KHN’s Fred Clasen-Kelly, who reported and wrote the latest KHN-NPR “Bill of the Month” feature, about a mysterious mishap during minor surgery.
Readers and Tweeters Decry Medical Billing Errors, Price-Gouging, and Barriers to Benefits
KHN gives readers a chance to comment on a recent batch of stories.
Treating Long Covid Is Rife With Guesswork
With a dearth of evidence on effective treatments for long covid, patients and doctors in 400 clinics around the country still rely on trial and error.